Sales and Marketing

Showing 15 posts of 11520 posts found.

EMA approves Cimzia for use in treating plaque psoriasis

July 2, 2018 Sales and Marketing Cimzia, EMA, UCB, indication, pharmaceutical

The Brussels-based pharmaceutical company UCB has announced that the European Medicines Agency (EMA) has approved a label extension for Cimzia …
roche__tree

Roche’s Tecentriq combo gives strong Phase 3 showing in triple negative breast cancer

July 2, 2018 Research and Development, Sales and Marketing Cancer, Roche, breast cancer, pharma

Roche has unveiled new Phase 3 data on its immunotherapy drug Tecentriq (atezolizumab) in combination with chemotherapy (Celgene’s Abraxane) as …
astrazeneca-sign

AstraZeneca chalks up double Japanese approval in lung and breast cancer

July 2, 2018 Sales and Marketing AstraZeneca, Cancer, Imfinzi, NSCLD, breast cancer, lung cancer, lynparza, pharma

It’s a big step forward for AstraZeneca’s global marketing operations as the company announced that two of its products have …
takeda_usa_pharmaceuticals_u

Takeda’s Entyvio secures Japanese approval in ulcerative colitis

July 2, 2018 Sales and Marketing Entyvio, Japan, Takeda, pharma, ulcerative colitis

Takeda Pharmaceutical has announced that its monoclonal antibody, Entyvio (vedolizumab), has been approved for the treatment of patients with moderately …
abbvie_0

AbbVie ordered to pay $448m over generic delays

July 2, 2018 Sales and Marketing AbbVie, FTC, androgel, besins, branded generics, pharma

A US Judge has ordered pharmaceutical company AbbVie to pay $448 million after determining that the company had used sham …

Novartis spins off Alcon as CEO focuses drug search

June 29, 2018 Medical Communications, Sales and Marketing Alcon, Novartis, eye care, pharma

Novartis has announced a plan to spinoff Alcon – its eye care division – into a separately-traded standalone company.Novartis has …

Pfizer’s Xeljanz scores EU approval for active psoriatic arthritis

June 29, 2018 Medical Communications, Sales and Marketing EU, Europe, Pfizer, Xeljanz, pharma, psoriatic arthritis

Pfizer has announced that the European Commission (EC) has approved Xeljanz in combination with methotrexate (MTX) for the treatment of …

NICE turns down Roche’s Ocrevus in early primary progressive multiple sclerosis

June 29, 2018 Medical Communications, Sales and Marketing NICE, Ocrevus, Roche, pharma

Roche’s sometimes strained relationship with NICE continues as the health watchdog for England and Wales chose to reject the former’s …
amazon

Amazon makes first move into healthcare with online pharmacy acquisition

June 28, 2018 Medical Communications, Sales and Marketing amazon, pharma, pharmacy

It’s been thought to have been on the cards for some time, but now, after much speculation, retail giant Amazon …

Roche’s Alecensa secures NICE approval in NSCLC after topping Pfizer’s Xalkori

June 28, 2018 Sales and Marketing Alecensa, NICE, NSCLC, Pfizer, Xalkori, pharma

UK health watchdog NICE has given its approval for Roche’s selective ALK inhibitor Alecensa (alectinib) for use on the NHS, …
amgen_hq

Amgen biosimilar proves non-inferior to J&J’s Remicade in rheumatoid arthritis

June 27, 2018 Research and Development, Sales and Marketing Amgen, Johnson & Jonson, Remicade, pharma, rheumatoid arthritis

Amgen has unveiled new Phase 3 data for its biosimilar version of Johnson & Johnson’s Remicade (infliximab), confirming that it …
abbvie_0

Abbvie and Google’s Calico extend age-related disease partnership to $2.5bn

June 27, 2018 Research and Development, Sales and Marketing AbbVie, Cancer, Goggle, calico, pharma

The partnership of Abbvie and Google’s Calico has announced they are to extend their existing 10-year drug discovery and development …
astrazeneca_building_white

AstraZeneca’s Lynparza proves efficacy in first-line BRCA-mutated advanced ovarian cancer

June 27, 2018 Research and Development, Sales and Marketing AstraZeneca, Cancer, MSD, Merck, ovarian cancer, pharma

AstraZeneca is celebrating alongside partner MSD with the reveal of new data on the use of Lynparza in the first-line …
fdaoutsideweb

FDA panels vote to reject Pain Therapeutics’ abuse-deterrent opioid drug

June 27, 2018 Research and Development, Sales and Marketing Remoxy, opioid crisis, opioids, pain therapeutics, pharma

Drug development firm Pain Therapeutics has revealed that its abuse-deterrent opioid medication Remoxy has been rejected by an FDA advisory …
The Gateway to Local Adoption Series

Latest content